Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors

Keyphrases

• Histone Deacetylase 1 (HDAC1) 100%
• Dual Inhibitor 100%
• Indoleamine 2,3-dioxygenase 1 (IDO1) 100%
• IC50 66%
• Antitumor Agents 66%
• Cancer Treatment 33%
• Cancer Cells 33%
• Pharmacokinetic Profile 33%
• Epigenetics 33%
• Cancer Immunotherapy 33%
• In Cancer 33%
• Proof of Concept Study 33%
• Highly Active 33%
• In Vivo Antitumor Activity 33%
• Orally Active 33%
• Histone Deacetylase Inhibitor (HDACi) 33%
• Kynurenine 33%
• Immunotherapeutics 33%
• Low Toxicity 33%
• Tumor Model 33%
• Targeting Mechanism 33%
• Novel Antitumor Agents 33%
• Dual Targeting 33%
• Cancer Epigenetics 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Anticarcinogen 100%
• Histone Deacetylase 100%
• Indoleamine 2,3 Dioxygenase 100%
• IC50 66%
• Pharmacokinetics 33%
• Immunotherapy 33%
• Lead Compound 33%
• Histone Deacetylase 1 33%
• Kynurenine 33%
• Tumor Model 33%
• Histone Deacetylase Inhibitor 33%